Pacific Northwest Clinical Center for the NHLBI PETAL Network
NHLBI PETAL 网络西北太平洋临床中心
基本信息
- 批准号:10225213
- 负责人:
- 金额:$ 32.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-01 至 2021-10-31
- 项目状态:已结题
- 来源:
- 关键词:Accident and Emergency departmentAcute Lung InjuryAdult Respiratory Distress SyndromeBiologicalBiologyCaringClinicalClinical DataClinical ManagementClinical ResearchClinical TrialsClinical Trials NetworkCommunity HospitalsComputerized Medical RecordConduct Clinical TrialsCritical CareCritical IllnessData CollectionDropsEarly treatmentEmergency MedicineEpidemiologistEpidemiologyFutureGoalsHealthHospitalsHypoxemiaImpairmentIncidenceInformation TechnologyInjuryInstitutionInterventionIntervention StudiesInvestigationLiquid substanceMonitorMorbidity - disease rateMulti-Institutional Clinical TrialNational Heart, Lung, and Blood InstituteOperative Surgical ProceduresOregonOutcomePacific NorthwestPathogenesisPatient-Focused OutcomesPatientsPharmacologyPreventionProtocols documentationPublicationsQuality ControlQuality of lifeRandomized Controlled Clinical TrialsRandomized Controlled TrialsRecoveryResearchResearch PersonnelResourcesRespiratory FailureRiskSafetySamplingScienceScientistSpecialistSpecimenSurvivorsSystemTestingTherapy Clinical TrialsTidal VolumeTraumaVentilatorWashingtonWorkclinical centerclinical data warehousecollaborative approachdesigndisease phenotypeexperiencehigh riskimprovedimproved outcomeinterdisciplinary approachmolecular phenotypemortalitymultidisciplinarynovelnovel therapeuticspatient subsetspreventprotocol developmentpublic health relevancerecruitrepositoryresponsescreeningsuccessventilationward
项目摘要
DESCRIPTION (provided by applicant): The goal of the Prevention and Early Treatment of Acute Lung Injury (PETAL) Network is to develop and conduct high-quality randomized, controlled clinical trials to prevent, treat and/or improve outcomes of patients with or at risk fo acute respiratory distress syndrome (ARDS) using a multidisciplinary and collaborative approach, and to collect biologic samples and clinical data necessary to determine the molecular phenotype of disease pathogenesis, response to therapy, and recovery. The specific objective of the Pacific Northwest Clinical Center is to participate in this clinical network in orer to expand upon the work we have done through the two previous ARDS Clinical Trials Networks since 1994.
ARDS is a form of hypoxemic respiratory failure that is common, often fatal, and associated with significant sequelae that have a long lasting impact on the health and quality of life of its survivors. While previous trials of pharmacologic agents have failed to decrease mortality of patients with ARDS, the first two NHLBI ARDS Networks have demonstrated that changes in ventilator and fluid management can profoundly improve patient outcome. Since the publication of the landmark study of low tidal volume ventilation in 2000, there has been a steady drop in the case fatality of ARDS.
The preceding NHLBI ARDS Networks proved the hypothesis that an investigator-directed network of clinical and research centers can design and conduct investigations that would improve outcomes for patients with ARDS. By expanding the focus beyond the ICU, this new network has the potential to be even more far- reaching. The proposed Pacific Northwest Clinical Center embodies the experienced, diverse, collaborative and multidisciplinary approach that will lead to PETAL's success. We are a team of academic and community hospitals; of critical care, trauma/surgical and emergency medicine specialists; and of clinical trialists, basic
scientists; epidemiologists, clinicians, and research coordinators, in both Seattle, Washington and Portland, Oregon. We believe that the opportunity to improve care and both short and long-term outcomes of critically ill patients is in the hands of this new PETAL Network. In this application, we will demonstrate why the Pacific Northwest Clinical Center will be an important part of this new Network's success.
描述(申请人提供):预防和早期治疗急性肺损伤(PETAL)网络的目标是开发和进行高质量的随机对照临床试验,以预防,治疗和/或改善急性呼吸窘迫综合征(ARDS)患者或有急性呼吸窘迫综合征(ARDS)风险的患者的结局,采用多学科和协作方法,并收集确定疾病发病机理的分子表型、对治疗的反应和恢复所必需的生物样品和临床数据。太平洋西北临床中心的具体目标是参与这个临床网络,以扩大我们自1994年以来通过前两个ARDS临床试验网络所做的工作。
ARDS是一种常见的低氧性呼吸衰竭,通常是致命的,并伴有严重的后遗症,对幸存者的健康和生活质量产生长期影响。虽然以前的药物试验未能降低ARDS患者的死亡率,但前两个NHLBI ARDS网络已经证明,呼吸机和液体管理的变化可以大大改善患者的预后。自2000年低潮气量通气的里程碑式研究发表以来,ARDS的病死率稳步下降。
之前的NHLBI ARDS网络证明了这样一个假设,即由临床和研究中心组成的由医生指导的网络可以设计和进行研究,从而改善ARDS患者的结局。通过将重点扩大到重症监护室以外,这个新的网络有可能更加深远。拟议的太平洋西北临床中心体现了经验丰富,多样化,协作和多学科的方法,将导致PETAL的成功。我们是一个团队的学术和社区医院;重症监护,创伤/外科和急诊医学专家;和临床试验,基础
科学家;流行病学家,临床医生和研究协调员,在西雅图,华盛顿和波特兰,俄勒冈州。我们相信,改善重症患者的护理以及短期和长期结果的机会掌握在这个新的PETAL网络手中。在这个应用程序中,我们将证明为什么太平洋西北临床中心将是这个新网络的成功的重要组成部分。
项目成果
期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Recall of clinical trial participation and attrition rates in survivors of acute respiratory distress syndrome.
- DOI:10.1016/j.jcrc.2021.04.006
- 发表时间:2021-08
- 期刊:
- 影响因子:3.7
- 作者:Carlton EF;Ice E;Barbaro RP;Kampuis L;Moss M;Angus DC;Banner-Goodspeed VM;Ginde AA;Gong MN;Grissom CK;Hou PC;Huang DT;Hough CTL;Talmor DS;Thompson BT;Yealy DM;Couper MP;Iwashyna TJ;NHLBI Prevention and Early Treatment of Acute Lung Injury (PETAL) Network
- 通讯作者:NHLBI Prevention and Early Treatment of Acute Lung Injury (PETAL) Network
Patients' Adaptations After Acute Respiratory Distress Syndrome: A Qualitative Study.
- DOI:10.4037/ajcc2021825
- 发表时间:2021-05-01
- 期刊:
- 影响因子:2.7
- 作者:Hauschildt, Katrina E.;Seigworth, Claire;Kamphuis, Lee A.;Hough, Catherine L.;Moss, Marc;McPeake, Joanne M.;Harrod, Molly;Iwashyna, Theodore J.
- 通讯作者:Iwashyna, Theodore J.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Catherine Lee Hough其他文献
Catherine Lee Hough的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Catherine Lee Hough', 18)}}的其他基金
Effective Primary care practices that Enhance Recovery Trajectories after pneumonia (EXPERT)
增强肺炎后康复轨迹的有效初级保健实践(专家)
- 批准号:
10717618 - 财政年份:2023
- 资助金额:
$ 32.66万 - 项目类别:
Effect of randomization to neuromuscular blockade on physical functional impairment and recovery in ARDS
神经肌肉阻滞随机化对 ARDS 患者身体功能损伤和恢复的影响
- 批准号:
10249878 - 财政年份:2021
- 资助金额:
$ 32.66万 - 项目类别:
Mentored Patient Oriented Research in ARDS and Critical Illness Outcomes
指导 ARDS 和危重疾病结果中以患者为导向的研究
- 批准号:
10689129 - 财政年份:2020
- 资助金额:
$ 32.66万 - 项目类别:
Mentored Patient Oriented Research in ARDS and Critical Illness Outcomes
指导 ARDS 和危重疾病结果中以患者为导向的研究
- 批准号:
10491660 - 财政年份:2020
- 资助金额:
$ 32.66万 - 项目类别:
Mentored Patient Oriented Research in ARDS and Critical Illness Outcomes
指导 ARDS 和危重疾病结果中以患者为导向的研究
- 批准号:
10249623 - 财政年份:2020
- 资助金额:
$ 32.66万 - 项目类别:
Mentored Patient Oriented Research in ARDS and Critical Illness Outcomes
指导 ARDS 和危重疾病结果中以患者为导向的研究
- 批准号:
9955342 - 财政年份:2020
- 资助金额:
$ 32.66万 - 项目类别:
Oregon Clinical and Translational Research Institute KL2 Program
俄勒冈临床和转化研究所 KL2 项目
- 批准号:
10197248 - 财政年份:2017
- 资助金额:
$ 32.66万 - 项目类别:
Effect of randomization to neuromuscular blockade on physical functional impairment and recovery in ARDS
神经肌肉阻滞随机化对 ARDS 患者身体功能损伤和恢复的影响
- 批准号:
9080061 - 财政年份:2016
- 资助金额:
$ 32.66万 - 项目类别:
相似海外基金
Combinatorial cytokine-coated macrophages for targeted immunomodulation in acute lung injury
组合细胞因子包被的巨噬细胞用于急性肺损伤的靶向免疫调节
- 批准号:
10648387 - 财政年份:2023
- 资助金额:
$ 32.66万 - 项目类别:
Lung epithelial cell-derived C3 in acute lung injury
肺上皮细胞衍生的 C3 在急性肺损伤中的作用
- 批准号:
10720687 - 财政年份:2023
- 资助金额:
$ 32.66万 - 项目类别:
Examining the role of TRMT1 and tRNA methylation in acute lung injury and ARDS
检查 TRMT1 和 tRNA 甲基化在急性肺损伤和 ARDS 中的作用
- 批准号:
10719249 - 财政年份:2023
- 资助金额:
$ 32.66万 - 项目类别:
Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
- 批准号:
10591804 - 财政年份:2023
- 资助金额:
$ 32.66万 - 项目类别:
MAP2K1 AND MAP2K2 IN ACUTE LUNG INJURY AND RESOLUTION
MAP2K1 和 MAP2K2 在急性肺损伤中的作用及缓解
- 批准号:
10741574 - 财政年份:2023
- 资助金额:
$ 32.66万 - 项目类别:
Development of a new treatment for COVID-19-related acute lung injury targeting the microbiota-derived peptide corisin
针对微生物群衍生肽 corisin 开发治疗 COVID-19 相关急性肺损伤的新疗法
- 批准号:
23K07651 - 财政年份:2023
- 资助金额:
$ 32.66万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Probing immunovascular mechanobiology in pneumonia-associated acute lung injury at the single capillary level
在单毛细血管水平探讨肺炎相关急性肺损伤的免疫血管力学生物学
- 批准号:
10679944 - 财政年份:2023
- 资助金额:
$ 32.66万 - 项目类别:
The amyloid precursor protein protects against acute lung injury
淀粉样前体蛋白可预防急性肺损伤
- 批准号:
10575258 - 财政年份:2023
- 资助金额:
$ 32.66万 - 项目类别:
Role of macrophages and miRNA in regulating lung macrophage polarization and lung pathogenesis during respiratory virus-induced acute lung injury in normal and diabetic Syrian hamsters.
正常和糖尿病叙利亚仓鼠呼吸道病毒引起的急性肺损伤期间巨噬细胞和 miRNA 在调节肺巨噬细胞极化和肺部发病机制中的作用。
- 批准号:
10701207 - 财政年份:2023
- 资助金额:
$ 32.66万 - 项目类别:
Roles of N-glycans on neutrophil beta2 integrins in progression of acute lung injury
N-聚糖对中性粒细胞β2整合素在急性肺损伤进展中的作用
- 批准号:
10837431 - 财政年份:2023
- 资助金额:
$ 32.66万 - 项目类别: